Apple Refuses to License Masimo's Tech Amid Apple Watch Ban

Tim Cook emphasizes appeal over settlement in the ongoing patent dispute, as sales continue without the blood oxygen feature.

Tim Cook confirms Apple will not license Masimo's blood oxygen technology, focusing instead on appealing the Apple Watch ban.
Despite the ban, Apple continues to sell the Apple Watch Series 9 and Ultra 2 in the U.S., with the blood oxygen feature disabled.
Masimo CEO Joe Kiani has expressed willingness for settlement talks, but claims Apple has not engaged in serious discussions.
The ongoing dispute has not significantly impacted Apple's sales, with the Wearables, Home, and Accessories category reporting higher than expected revenue.
Apple's strategy includes marketing the Apple Watch in other countries where Masimo's patents do not apply.